WARNING LETTER 

RE: 648077 

Date: January 10, 2023 

TO: Info@purecraftcbd.com – Jason Navarrete 

PureCraft LLC 

237 A St., PMB 70555 

San Diego, CA 92101-4003 

RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19) 

This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade 

Commission (FTC) reviewed your website at the Internet address https://purecraftcbd.com/ on December 

14, 2022 and January 6, 2023, respectively. We also reviewed your social media websites at 

https://www.facebook.com/purecraftcbd and https://www.instagram.com/purecraftcbd/, where you direct 

consumers to your website, https://purecraftcbd.com/, to purchase your products. The FDA has observed 

that your website offers cannabidiol (CBD) products for sale in the United States and that these products 

are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, 

these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, 

and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs 

under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these 

products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 

§ 331(a) and (d). 

There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been 

named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the 

virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of 

Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 

and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential 

declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures 

to protect consumers from certain products that, without approval or authorization by FDA, claim to 

mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that 

are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take 

1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus 

Disease 2019” (COVID-19). 

2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued 

Jan. 31, 2020, and subsequently renewed), available at

https://www.phe.gov/emergency/news/healthactions/phe/Pages/default.aspx. 3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) 

Outbreak (Mar. 13, 2020), available at https://trumpwhitehouse.archives.gov/presidential-actions/proclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak/. 
    Page 2 of 5 pages

immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, 

prevention, treatment, diagnosis, or cure of COVID-19. 

Some examples of the claims on your website that establish the intended use of your products and 

misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19 include: 

 From the July 1, 2022 blog post titled “CBD & COVID-19: NEW RESEARCH, NEW FINDINGS 

[JUNE 2022]” on your webpage https://purecraftcbd.com/blogs/news/cbd-and-covid-new-researchand-findings: 

“* This post covers research that was published since our July 6, 2021 postReviewing [sic] 

Research on CBD for COVID-19 Therapy (which we suggest reading if you need an overview of 

how COVID-19 works in the body). To the best of our knowledge, the studies referenced in this 

article all used therapeutic-grade CBD that was purer or contained higher concentrations of 

cannabidiol than what’s on the market for public consumption. . . . 

COVID Prevention & CBD . . . 

Early results show that therapeutic doses of CBD do have a protective effect against COVID. . . . 

According to the National Institute of Health’s COVID-19 Research initiative:(1) 

• CBD is the only cannabinoid that exhibited a protective quality. When paired with THC, the 

preventive effect diminished. 

• People who take CBD-based medications (like Epidiolex) reported fewer COVID diagnosis 

than other populations. 

• More research in humans is needed but CBD be [sic] part of the COVID prevention protocol 

— along with (not in place of ) vaccination, masking, and social distancing. 

CBD vs SARS-CoV-2 . . .

[T]he CBD does start to attach the virus very soon after the virus is introduced into your system. 

This anti-SARS-CoV-2 assault makes it so that the virus can’t spread or further develop. Basically, 

the CBD inhibits the virus’s capacity to replicate itself or change host cells in your body. CBD 

blocks the viral reproduction by activating the infected cell’s stress response, which makes it create 

virus-killing proteins. . . . 

CBD For COVID Symptoms 

According to a March 2022 article in Frontiers in Immunology, CBD has been shown to decrease 

the severity of COVID. It’s primarily doing this by counteracting the body’s inflammatory response 

to the SARS-CoV-2 virus. . . . . 

Will cannabis or cannabinoids protect you from COVID? 

Current research indicates that therapeutic doses of CBD may provide some protection from the 

SARS-CoV-2 virus. The purer or higher concentration the CBD, the more effective this intervention 

seems to be.” 

 From the July 6, 2021 blog post titled “REVIEWING RESEARCH ON CBD FOR COVID-19 

THERAPY” on your webpage https://purecraftcbd.com/blogs/news/reviewing-research-on-cbd-forcovid-19-therapy: 

“Interest from the medical community about the usefulness of CBD in battling the COVID-19 virus 

isn’t completely out of left field... 
    Page 3 of 5 pages

[S]everal studies have emerged that are expected to progress our understanding of CBD’s 

therapeutic potential for COVID patients. . . . 

Hypothesis #1: CBD May Be An Option For COVID-19 Prevention 

Since contracting COVID-19 puts some at a higher risk of death and long-term effects, one study is 

focusing on the use of CBD for infection prevention. . . . They cultivated 800 new strains of 

Cannabis sativa L. Of these, 13 high-CBD strains were selected, which decreased the presence of 

ACE2 in 3D models of human respiratory and intestinal tissues. . . . 

Hypothesis #2: CBD May Reduce Inflammation Related To COVID-19 

 Can CBD help combat inflammation from a cytokine storm caused by COVID-19? 

Two studies using in vitro lung cell cultures have completed early stages of answering this 

question.(5, 6) 

In the first study, the lung cultures were infected with the SARS-CoV-2 virus. . . . The high-CBD 

formula reduced inflammation considerably, whereas the high-THC formula had little antiinflammatory effect. The high-CBD formula reduced the specific cytokines responsible for the 

COVID-19-induced cytokine storm. . . . 

In the second study, CBD was found to halt viral replication. The researchers also concluded that 

CBD was more effective than THC. In fact, of the cannabinoids that were tested, CBD was found to 

be the only cannabinoid that produced this outcome. This study has not yet been peer reviewed, 

but is a promising line of investigation. 

Hypothesis #3: CBD May Be Helpful In The Treatment Of COVID-19 . . . 

In another study performed on mice experiencing respiratory distress due to an artificially-induced 

cytokine storm, CBD reversed the negative effects and restored homeostasis.(8) This suggests 

that CBD may support recovery from the virus. 

Current Findings Spark More Questions 

With the facts on the known relationship between CBD and COVID-19 laid out, it’s clear that further 

research and incoming results will reveal CBD’s role and effectiveness as a therapeutic tool. For 

now, the medical community and the world have earmarked these findings as a pivotal and 

encouraging chapter amidst the rollercoaster plot of the COVID-19 pandemic.” 

 From a July 10, 2022 post on your Instagram webpage 

https://www.instagram.com/p/Cf2HNUtJLtQ/, and a July 8, 2022 post on your Facebook webpage 

https://www.facebook.com/purecraftcbd, which links to your July 1, 2022 blog post: 

“CBD & COVID-19: NEW RESEARCH, NEW FINDINGS [JUNE 2022] . . . 

So, keep reading for the latest coronavirus-CBD research on: 

- Whether preventing COVID with CBD is possible 

- How CBD interacts with the SARS-CoV-2 (the virus that causes COVID) 

- The COVID and cannabinoid receptors link 

- Potential CBD benefits for COVID symptoms 

- If CBD can curb COVID vaccination side effects” 

 From a July 6, 2021 post on your Facebook webpage https://www.facebook.com/purecraftcbd, 

which links to your July 6, 2021 blog post:
    Page 4 of 5 pages

“REVIEWING RESEARCH ON CBD FOR COVID-19 THERAPY. . . CBD is being examined as a 

possible therapy for COVID-19 . . . .” 

You should take immediate action to address this matter. This letter is not meant to be an all-inclusive list 

of violations that exist in connection with your products or operations. It is your responsibility to ensure 

that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We 

advise you to review your websites, product labels, and other labeling and promotional materials to ensure 

that you are not misleadingly representing your products as safe and effective for a COVID-19-related use 

for which they have not been approved by FDA and that you do not make claims that misbrand the 

products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-TaskForce-CDER@fda.hhs.gov describing the specific steps you have taken to address any violations. 

Include an explanation of each step being taken to prevent the recurrence of any violations, as well as 

copies of related documentation. Failure to adequately correct any violations may result in legal action, 

including, without limitation, seizure and injunction. 

FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, 

or authorized by FDA and that are being misleadingly represented as safe and/or effective for the 

treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms 

and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 

related products in violation of the FD&C Act. This list can be found at 

http://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-covid-19-products. 

Once you have taken actions to address the sale of any unapproved and unauthorized products for the 

mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions 

have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken 

such corrective actions. 

This letter notifies you of our concerns and provides you with an opportunity to address them. If you 

cannot take action to address this matter completely within 48 hours, state the reason for the delay and 

the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, 

include your reasoning and any supporting information for our consideration. 

If you are not located in the United States, please note that products that appear to be misbranded or 

unapproved new drugs may be detained or refused admission if they are offered for importation into the 

United States. We may advise the appropriate regulatory officials in the country from which you operate 

that FDA considers your product(s) referenced above to be unapproved and misbranded products that 

cannot be legally sold to consumers in the United States. 

Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov. 

FTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to 

advertise that a product can prevent, treat, or cure human disease unless you possess competent and 

reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, 

substantiating that the claims are true at the time they are made. For COVID-19, no such study is 

currently known to exist for the products identified above. Thus, any coronavirus-related prevention or 

treatment claims regarding such products are not supported by competent and reliable scientific evidence. 

You must immediately cease and desist making all such claims. Violations of the FTC Act may result in 

legal action seeking a Federal District Court injunction and an order may require that you pay back money 

to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, 

of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about 

the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 

per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 

19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, 

Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that 
    Page 5 of 5 pages

you have ceased making unsubstantiated claims for the product identified above. If you have any 

questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244. 

 

 Sincerely, 

 

CAPT Tina Smith 

Acting Director 

Office of Unapproved Drugs and Labeling Compliance 

Center for Drug Evaluation and Research 

Food and Drug Administration 

 Sincerely, 

 

Serena Viswanathan 

 Associate Director 

 Division of Advertising Practices 

 Federal Trade Commission